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Abstract
Purpose: Two-stage single-arm trial designs are commonly used in phase II oncology to infer treatment
effects for a binary primary outcome (e.g., tumour response). It is imperative that such studies be
designed, analysed, and reported effectively. However, there is little available evidence on whether this is
the case, particularly for key statistical considerations. We therefore comprehensively review such trials,
examining in particular quality of reporting.
Methods: Published oncology trials that utilised “Simon’s two-stage design” over a 5 year period were
identified and reviewed. Articles were evaluated on whether they reported sufficient design details, such
as the required sample size, and analysis details, such as a confidence interval (CI). The articles that did
not adjust their inference for the incorporation of an interim analysis were re-analysed to evaluate the
impact on their reported point estimate and CI.
Results: Four hundred and twenty five articles that reported the results of a single treatment arm were
included. Of these, 47.5% provided the five components that ensure design reproducibility. Only 1.2%
and 2.1% reported an adjusted point estimate or CI, respectively. Just 55.3% of trials provided the final
stage rejection bound, indicating many trials did not test the hypothesis the design is constructed to
assess. Re-analysis of the trials suggests that reported point estimates underestimated treatment effects
and that reported CIs were too narrow.
Conclusion: Key design details of two-stage single-arm trials are often unreported. Whilst inference
is regularly performed, it is rarely done so in a way that removes the bias introduced by the interim
analysis. In order to maximise their value, future studies must improve the way that they are analysed
and reported.
Keywords: Adaptive design; Cancer; Estimation; Oncology; Phase II; Simon.
Introduction
Whilst randomised trial designs are becoming more commonplace in phase II oncology1, recent analyses
indicate that single-arm trial designs remain the most widely utilised in this setting2. Furthermore, the
primary outcome variable is often dichotomous in phase II2; typically chosen as objective response1 via
RECIST3. Within the available class of single-arm trial designs for a binary primary outcome, what
is commonly referred to as “Simon’s two-stage design”4 is generally preferred5. The reasons for this
preference are many, but principally Simon’s proposal has been seen to provide a constructive means of
formally testing for an efficacy signal via a simple design that requires only small sample size1.
The habitual use of Simon’s two-stage design has seen much research be conducted in to its effective
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utilisation. Recent work in this area includes methodology to account for deviation from the planned
design6,7,8, explorations of new criteria for simultaneously optimising the design and analysis9, and
evaluations of the value of such trials within wider phase II development plans10. Indeed, an extensive
list of publications have now addressed how to handle numerous issues that can arise in trials that use
this design. Nonetheless, it is not known to what extent the advice provided in these publications has
permeated through to practice.
Several authors have evaluated the reporting of phase II oncology trials without differentiating by
design. For example, Grellety et al.11 reviewed 156 phase II oncology trials published in 2011, assessing
quality of reporting using two proposed scores. One of these, the Key Methodological Score (KMS),
consisted of 3 items: provision of (i) a clear definition of a criterion of principal judgement, (ii) a clear
justification of the number of patients included, and (iii) a clear definition of the population on which the
principal/secondary judgement criteria were evaluated. They found that the median KMS was 2/3, whilst
only 16.1% of the analysed studies had a KMS of 3/3. Furthermore, Langrand-Escure et al.2 reviewed
557 phase II and phase II/III oncology trials published in 2010-15 in three high-impact oncology journals,
also appraising quality of reporting using the KMS. They concluded just 26.2% of articles had a KMS of
3/3. They additionally found that a sample size calculation was missing in 66% of the analysed articles.
These findings are concerning, but it is possible that they only scratch the surface of the issues in the
use of two-stage single-arm designs in practice. In particular, to date, no paper has sought to ascertain
the degree to which precise specific components of the design of such trials (e.g., the sample size required
in each stage) is included in published reports. Moreover, no research has evaluated the frequency with
which trialists have heeded the recommendations of the many articles that argue for the need for inference
to be adjusted to account for the interim analysis. Finally, the extent to which deviation from the planned
design occurs in practice, or the impact of this on type-I and type-II error-rates, is unknown. Given the
extent of the phase II evidence base that comes from trials utilising two-stage single-arm designs, it is
paramount that such studies be designed, analysed, and reported effectively. Therefore, with so little
known about whether this is the case, we sought to systematically review a large number of trials that
utilised Simon’s two-stage design to ascertain issues in design, analysis, and reporting.
Methods
Two-stage group-sequential single-arm trial designs for a binary primary out-
come
We review phase II trials that used Simon’s two-stage design. We therefore briefly summarise the statis-
tical aspects of such trials.
The design evaluates a binary primary outcome, xi ∈ {0, 1} from patient i, assumed to be distributed
as Xi ∼ Bern(p). Thus, p is the probability of success for the primary outcome. The following hypothesis
is tested: H0 : p ≤ p0, with the type-I error-rate controlled to α ∈ (0, 1) when p = p0. The trial is
powered to level 1− β ∈ (0, 1) when p = p1 > p0. Here, p0 and p1 are respectively commonly referred to
as the maximal success probability that does not warrant further investigation and the minimal success
probability that allows further investigation of the treatment. Often, p0 is based on the historical success
probability for the current standard-of-care.
The design includes a single interim analysis for futility (or a no-go decision) and is indexed by four
values: a1, a, n1 and n. In stage 1, outcomes for n1 patients are accumulated. If sn1 =
∑n1
i=1 xi ≤ a1
the trial terminates for futility with H0 not rejected. Otherwise, outcomes for a further n2 = n − n1
patients are gathered. Then, H0 is rejected if sn =
∑n
i=1 xi > a and not rejected otherwise. The design
parameters, a1, a, n1, and n, are typically chosen as those that minimise some optimality criteria, amongst
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the combinations that meet the type-I error and power requirements. Simon4 suggested two optimality
criteria: (i) null-optimal, to minimise the expected sample size when p = p0 and (ii) minimax, to minimise
the maximal sample size n. Other optimality criteria have since been proposed12,13,14.
Post-trial inference could be performed using methods developed for one-sample proportions. For
example, a confidence interval (CI) could be computed using the Clopper-Pearson15 approach. Depending
on the stage of termination, a point estimate for p could be given as pˆ = sn1/n1 or sn/n. However, it is
well known that the inclusion of an interim analysis necessitates that adjusted inference be performed in
order to compute p-values that are consistent with the decision on H0, to acquire CIs with the desired
coverage, and to reduce the bias in the point estimate16. Many such adjusted methods have been
proposed, including that of Jung et al.17 for p-values, Jennison and Turnbull18 for CIs, and Jung and
Kim19 for point estimates. A selection of methods for handling deviation from the planned design (i.e.,
scenarios in which the interim or final analysis is conducted with a sample size different from n1 or
n respectively) have also been developed6,7,8,20. We provide details on all methods used later in the
Supplementary Materials.
Literature review
Further details on the literature review are included in the Supplementary Materials. Key points are
given here.
Inclusion criteria
To identify articles for potential inclusion, PubMed was searched on February 21 2018 using the fol-
lowing term: (“2013/01/01”[Date - Publication] : “2017/12/31”[Date - Publication]) AND Clinical
Trial[Publication Type] AND (phase II[Title/Abstract] OR phase 2[Title/Abstract]) AND (cancer[All
Fields] OR oncology[All Fields]). This returned 5344 articles for review.
The key inclusion criteria were: (i) full-length articles (i.e., no short communications), (ii) primary
publications on a trial’s complete results (i.e., no secondary or preliminary analyses), and (iii) reports
results for at least one treatment arm that was designed and analysed using “Simon’s two-stage design”.
Five hundred and thirty-four of the 5344 returned articles (10.0%) were randomly selected for evalu-
ation for inclusion by MJG and APM. The authors agreed on inclusion for 520 articles (97.3%). Given
the high-level of agreement and the low number of reasons for disagreement, the remaining articles were
assessed for inclusion by MJG only, with discussion with APM where required.
Data extraction
Data on each of the questions listed in Table 1 was extracted by MJG for each arm, in each article,
deemed eligible for inclusion. To establish the reliability of this extraction, data extracted by MJG was
compared with that independently extracted on 58 arms by APM. Across 14 questions requiring non-
binary value extraction (e.g., ‘Q5. What was the value of p0?’) the duplicate extractions agreed 96.2%
of the time. Across a wider set of 26 questions, including those requiring only binary value extraction,
the duplicate extractions agreed 94.3% of the time. The final extracted data is reported as percentages
or through figures as appropriate.
Trial re-analyses
Given absence of evidence is not evidence of absence, included articles that did not state they reported
an adjusted point estimate (Q25) were re-analysed where possible (i.e., subject to reporting the required
design components). This enabled evaluation of which of seven possible point estimates (the unadjusted
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Table 1: The questions for which data was extracted for all included treatment arms.
Question Statement
Q1 How many included treatment arms are reported in this article?
Q2 What type of cancer was the article focused on?
Q3 Does the article use the phase “Simon two-stage”, or similar, or cite Simon (1989)4?
Q4 What was the chosen design optimality criteria?
Q5 What was the value of p0?
Q6 Was a justification given for the value of p0?
Q7 What was the value of p1?
Q8 What was the value of α?
Q9 What was the value of β?
Q10 What was the value of a1?
Q11 What was the value of a?
Q12 What was the value of n1?
Q13 What was the value of n?
Q14 Was a target recruitment goal larger than n stated?
Q15 What stage did the trial terminate?
Q16 If ‘2’ to Q15, did they explicitly state the criteria for progression to stage 2 was met?
Q17 If ‘2’ to Q15, what was the realised sample size in stage 1?
Q18 If ‘2’ to Q15, what was the number of successes in stage 1?
Q19 Did the stage of termination have to be inferred from the enrolled/analysed sample size?
Q20 What was the total enrolled sample size?
Q21 Did they report a point estimate, p-value, or confidence interval?
Q22 If ‘Yes’ to Q21, what was the sample size assumed in the analysis?
Q23 If ‘Yes’ to Q21, what was the total number of successes assumed in the analysis?
Q24 If ‘Yes’ to Q21, did they report a point estimate?
Q25 If ‘Yes’ to Q24, did they state they used an adjusted point estimate?
Q26 If ‘Yes’ to Q24, what was the reported point estimate?
Q27 If ‘Yes’ to Q21, did they report a p-value?
Q28 If ‘Yes’ to Q27, did they state they used an adjusted p-value?
Q29 If ‘Yes’ to Q27, what was the reported p-value?
Q30 If ‘Yes’ to Q21, did they report a confidence interval?
Q31 If ‘Yes’ to Q30, did they state they used an adjusted confidence interval?
Q32 If ‘Yes’ to Q30, what confidence interval level was used?
Q33 If ‘Yes’ to Q30, what was the reported confidence interval’s lower limit?
Q34 If ‘Yes’ to Q30, what was the reported confidence interval’s upper limit?
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estimate and six adjusted estimates) the reported point estimate (Q26) was consistent with, to the
reported number of decimal places.
Equivalent computations were conducted for those articles that did not state they reported an adjusted
CI (Q30); the reported CI (Q32-34) was compared for its consistency with four unadjusted and two
adjusted CIs.
The re-analyses were limited to those trials (i) adjudged to have terminated in stage 2, as point
estimate and CI procedures do not in general adjust when a trial terminates in stage 1 and (ii) that
reported the number of successes and sample size assumed in the analysis, as these are required to
calculate unadjusted point estimates and CIs. To re-analyse using the adjusted inferential procedures,
a1 and n1 were additionally required to have been reported clearly, as these are requisite to adjusted
inference.
Results
Included articles
Five hundred articles were deemed eligible for inclusion. Four hundred and twenty-five of these reported
the results of a single eligible treatment arm. The remaining 75 articles reported results for an additional
204 eligible treatment arms (arms per article: median 2, range [2,15]).
To remove the need to account for skew caused by the quality of the articles reporting multiple
included treatment arms, we discuss here the findings for only the 425 included articles that reported
the results of a single eligible treatment arm. Findings for the remaining 75 articles are given in the
Supplementary Materials.
Table 2 provides descriptors on the 425 articles. At least 15.8% of the articles came from each allowed
publication year, with a decline in inclusion by year potentially indicating decreasing use of the considered
design type. The included articles were published in 100 distinct journals, with more than ten articles
included for nine journals. The type of cancer under consideration varied widely, though lung and lymph
cancers together accounted for 26.4% of the articles.
One hundred and ten trials (25.9%) were judged to have terminated in stage 1, in contrast to 298
in stage 2 (70.1%). Amongst the 298 judged to have terminated in stage 2, only 80 (26.4%) stated the
criteria had been met for progression to stage 2; indicating that this judgement often had to be based on
the enrolled and analysed sample sizes. For 17 articles (4.0%) it was not possible to ascertain when the
trial terminated; this was caused by the final sample size being between n1 and n, or because neither of
the planned stage-wise sample sizes were reported.
Reporting of design characteristics
Extracted data on the reporting of design characteristics is summarised in Table 3. Whilst 380 articles
(89.4%) clearly stated p0, only 78 (18.4%) provided a justification for this value. The success probability
p1 was often reported (391 articles; 92.0%), as were the desired type-I (372 articles; 87.5%) and type-II
error-rates (382 articles; 89.9%). The chosen optimality criteria was stated in only 240 articles (56.5%).
This is the principal driver of the fact that only 202 articles (47.5%) reported p0, p1, α, β, and the
optimality criteria; the five components that ensure a design can be easily reproduced.
Whilst a1 (349 articles; 82.1%), n1 (371 articles; 87.3%), and n (394 articles; 92.7%) were all regularly
reported, a was given in only 235 articles (55.3%). This drives the result that just 221 articles (52.0%)
reported the four components a1, a, n1, and n; those that enable a design’s operating characteristics to
be computed for any p.
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Table 2: Descriptors on the 425 included articles that reported the results of a single eligible treatment
arm. The denominator for computing percentages (given to 1 decimal place) is 425 in all instances.
Descriptor Value Number (%)
Publication year 2013 102 (24.0)
2014 101 (23.8)
2015 79 (18.6)
2016 76 (17.9)
2017 67 (15.8)
Journal Cancer Chemother Pharmacol 44 (10.4)
Ann Oncol 30 (7.1)
Invest New Drugs 23 (5.4)
Lung Cancer 17 (4.0)
Cancer 15 (3.5)
BMC Cancer 13 (3.1)
J Clin Oncol 13 (3.1)
Br J Haematol 11 (2.6)
Lancet Oncol 11 (2.6)
Other (91 journals) 248 (58.4)
Cancer Lung 59 (13.9)
Lymph 53 (12.5)
Colon/rectum 32 (7.5)
Breast 28 (6.6)
Stomach 25 (5.9)
Head and neck 23 (5.4)
Blood 22 (5.2)
Kidney 21 (4.9)
Other 162 (38.1)
Stage of termination 1 110 (25.9)
2: Stated the criteria had been met for progression 80 (18.8)
2: Did not state the criteria had been met for progression 218 (51.3)
Unclear 17 (4.0)
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Figure 1 depicts the values for p0 and p1 given in the 373 articles (87.8%) that reported both of these
quantities. The median value of p1 − p0 was 0.2.
Table 3: Reporting of the design of the 425 included articles that reported the results of a single eligible
treatment arm. The denominator for computing percentages (given to 1 decimal place) is 425 in all
instances.
Criteria Number (%)
Used the phrase “Simon two-stage” (or similar) or cited Simon (1989)4 357 (84.0)
Clearly stated p0 380 (89.4)
Gave a justification for p0 78 (18.4)
Citation given 40 (9.4)
Justification given but no citation 38 (8.9)
Clearly stated p1 391 (92.0)
Clearly stated α 372 (87.5)
α = 0.05 231 (54.4)
α = 0.1 103 (24.2)
Clearly stated β 382 (89.9)
β = 0.1 165 (38.8)
β = 0.2 173 (40.7)
Clearly stated the optimality criteria 240 (56.5)
Null-optimal 142 (33.4)
Minimax 93 (21.9)
Admissable 4 (0.9)
Other 1 (0.2)
Clearly stated a1 349 (82.1)
Clearly stated a 235 (55.3)
Clearly stated n1 371 (87.3)
Clearly stated n 394 (92.7)
Indicated the recruitment target was greater than n 117 (27.5)
Clearly stated p0 and p1 373 (87.8)
Clearly stated p0, p1, α, and β 340 (80.0)
Clearly stated a1, a, n1, and n 221 (52.0)
Clearly stated p0, p1, α, β, and the optimality criteria 202 (47.5)
Clearly stated p0, p1, α, β, the optimality criteria, a1, a, n1, and n 109 (25.6)
Reporting of inferential procedures
Extracted data on the reporting of the inferential procedures performed in the 425 included articles is
summarised in Table 4, with additional stratification by stage of termination.
In total, 375 articles (88.2%) reported either a point estimate, p-value, or CI for their primary outcome.
This figure was larger for the trial’s adjudged to have terminated in stage 2 (287/298 articles; 96.3%).
Whilst point estimates were often reported (372 articles; 87.8%), only 5 articles (1.2%) stated that
they had reported an adjusted point estimate. In contrast, p-values were rarely reported (4 articles;
1.3%). For CIs, just 233 articles (54.8%) reported any type of CI, with only 9 (2.1%) indicating that
they reported an adjusted CI.
To evaluate whether the articles that reported a point estimate or CI but did not indicate it was
adjusted were consistent (to their reported number of decimal places) with unadjusted or adjusted anal-
yses, the trials were re-analysed (Table 5). Two hundred and seventy (96.1%) of the re-analysed articles
reported point estimates consistent with an unadjusted estimate. However, 133/228 articles (58.3%)
for which adjusted point estimates could be calculated were also consistent with at least one adjusted
estimate. For the CIs, 116/178 articles (65.2%) that were re-analysed were consistent with at least one
unadjusted interval. Far fewer articles (3/140; 2.1%) for which adjusted intervals could be computed
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Figure 1: The combinations of p0 and p1 given in the 373/425 articles (87.8%) that reported both of these
components is depicted. The size of the circles indicates the number of articles that had a particular
combination. Densigrams are given on the axes to display the marginal distributions of p0 and p1. The
dotted line indicates the lower quartile (0.15) of the distribution of p1 − p0; the dashed line indicates the
median and upper quartile (0.2) of this distribution.
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were consistent with at least one adjusted interval.
To visualise the impact of not utilising adjusted inferential procedures, Figure 2A displays the unad-
justed estimate (pˆnaive) against the uniform minimum variance unbiased estimate
19 (UMVUE, pˆumvue)
for the 233 trials that terminated in stage 2 where the UMVUE could be computed. The difference
between the unadjusted estimate and the UMVUE is presented as a percentage of p1 − p0 in Figure 2B.
Together, these plots indicate that whilst the difference between the unadjusted and adjusted estimates
may often be small, there are instances in which it is large; in 25 cases more than 25% of the difference
p1 − p0.
Similar visualisations are provided in Figure 3. Figure 3A displays the length of the reported unad-
justed CI against the length of the corresponding adjusted CI proposed by Jennison and Turnbull18 for
the 140 trials for which this adjusted CI could be computed. Figure 3B compares the respective coverage
of these unadjusted and adjusted CIs when p = pˆumvue for the 131 trials in which the target coverage was
0.95. In general, the length of the unadjusted CI is shorter than the corresponding adjusted CI, which is
reflected in the coverage being below the desired level for the unadjusted procedure in several instances.
Table 4: Reporting of inferential procedures performed in the 425 included articles that reported the
results of a single eligible treatment arm, with additional stratification by stage of termination. The
denominators for computing percentages (given to 1 decimal place) in the three columns are 110, 298,
and 425 respectively unless stated otherwise.
Criteria Stage 1 Stage 2 All
Number (%) Number (%) Number (%)
Reported a point estimate, p-value, or confidence 72 (65.5) 287 (96.3) 375 (88.2)
interval for the primary outcome
Reported a point estimate 70 (63.6) 287 (96.3) 372 (87.8)
Stated the point estimate had been adjusted for 0 (0) 5 (1.7) 5 (1.2)
the two-stage design
Reported a p-value 0 (0) 4 (1.3) 4 (0.9)
Stated the p-value had been adjusted for the 0 (0) 3 (1.0) 3 (0.7)
two-stage design
Reported a confidence interval 40 (36.4) 187 (62.8) 233 (54.8)
Stated the confidence interval had been 0 (0) 9 (3.0) 9 (2.1)
adjusted for the two-stage design
Analysis performed assuming a sample equal 27/70 (38.6) 72/278 (25.9) 99/348 (28.4)
to that given in the design
Table 5: Re-analysis of the subset of the 425 articles that reported a point estimate or confidence interval
not stated to have been adjusted. Consistency is measured in all cases against the reported number of
decimal places. The denominators for computing percentages (given to 1 decimal place) are given in each
row. Note that the re-analysis is limited to those articles that were judged to have terminated in stage 2.
Criteria Number (%)
Reported a point estimate not stated as adjusted and clearly reported the 281/298 (94.2)
number of successes and sample size assumed in the analysis
Reported point estimate consistent with an unadjusted estimate 270/281 (96.1)
Reported point estimate consistent with at least one adjusted estimate 133/228 (58.3)
Reported a confidence interval not stated as adjusted and clearly reported its 178/298 (59.7)
level, the number of successes, and sample size assumed in the analysis
Reported confidence interval consistent with at least one unadjusted interval 116/178 (65.2)
Reported confidence interval consistent with at least one adjusted interval 3/140 (2.1)
Finally, note that 348 trials that were judged to have ended in stage 1 or stage 2 reported a point
estimate, p-value, or CI, as well as the sample size required by their design. Amongst these, just 99
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Figure 2: In A, a comparison of the naive unadjusted point estimate (pˆnaive) and the uniform minimum
variance unbiased estimate (UMVUE, pˆumvue) is given for the 233 trials that terminated in stage 2
where the UMVUE could be computed. In B, the difference between pˆnaive and pˆumvue is presented as a
percentage of p1 − p0, along with a boxplot to indicate the distribution of this data.
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Figure 3: In A, the length of the reported unadjusted CI is compared to the length of the corresponding
adjusted CI proposed by Jennison and Turnbull18 for the 140 articles for which this adjusted CI could be
computed. In B, the respective coverage of these unadjusted and adjusted CIs when p = pˆumvue is given
for the 131 of these articles in which the target coverage was 0.95. In both cases, points are coloured
by the unadjusted CI that the re-analysis indicated the reported CI matched with. For those CIs that
matched none of the unadjusted CIs, Clopper-Pearson15 was used to compute the coverage.
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Figure 4: A comparison of the sample size required by the design and that assumed in the analysis for
348 articles. Colour indicates the judged stage of trial termination.
(28.4%) performed their analysis using the planned sample size. Differences in the planned and analysed
sample sizes are shown in Figure 4.
Discussion
A large proportion of all phase II evidence comes from trials conducted using Simon’s two-stage design,
as exemplified by the number of articles found to be eligible in this review. This necessitates that such
studies be designed, analysed, and reporting effectively. We evaluated the degree to which this is true
through a comprehensive review of trials conducted over a 5 year period.
It is easy to argue that the reporting of design components was poor. In particular, the reproducibility
of determined designs is limited by infrequent reporting of p0, p1, α, and β in unison. It is also alarming
that only 18.4% of trials provided a justification for p0, considering the interpretation of study results
is highly dependent on this value. Furthermore, it may be considered disappointing that so many trials
chose standard target error-rates (e.g, α = 0.05), as it has been highlighted that small concessions in
this regard can lead to notable efficiency gains21. Similar statements are true of the chosen optimality
criteria, with previous work noting that the often-used minimax and null-optimal designs may routinely
not be the most advisable choice13,22.
Few articles stated that they utilised adjusted inferential procedures. Given there is no additional
cost to using these methods, this is a disappointing finding. Figures 3 and 4 together indicate that the
result of this in practice may be that phase II trials utilising Simon’s two-stage design are conservative
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in their reported point estimate, but anti-conservative in the width of their CI. It is also surprising that
only 54.8% of articles included a CI of any kind. The size of single-arm trials makes the uncertainty
around a point estimate important to quantify; we encourage future studies to include such details.
Many final analyses were performed with a sample size different from that specified in the design
(71.6%); this is not surprising given many trials indicated they planned to over-recruit to allow for
attrition (Table 3). This highlights the need for trialists to plan for such design deviation, and echoes
previous findings from Koyama and Chen23. We initially hoped to extract data on how trials handled
design deviation when interpreting their results. This was ultimately judged to be too subjective an
endeavour to complete, as many studies interpreted their findings through informal comparison of their
point estimate or CI bounds to p0 and/or p1.
The difficulties in practice of attaining the planned sample size may be reflected in the fact that
only 55.3% of trials reported a. This lack of reporting of a also indicates that many trials that utilise
Simon’s two-stage design do not formally test the hypothesis they claim to. We note that methodology
to comprehensively handle over- and under-running is available. Its use is depicted in Figure 5, which
provides the error-rates for 45 trials when the methodology of Englert and Kieser7 is implemented.
Using this methodology, trials are assured to conform to their desired type-I error-rate, and it appears
sample sizes that enable power to reach close to the desired level may have been achieved in practice. As a
contrast, the error-rates if a was retained at the final analysis are also shown, while other possible methods
of interpreting trial results are given in the Supplementary Materials. We note that without utilising
established methodology to specifically account for design deviation, many trials may be interpreting
their findings in a manner associated with a high probability of erroneous decision making.
We acknowledge a number of limitations to our work. Firstly, only a 10% duplicate extraction was
performed. Given the strength of our findings, though, we note that it is unlikely our conclusions would
be altered by additional duplicate extractions. It is also impossible to be certain that those trials that
did not state they utilised an adjusted inferential procedure had used an unadjusted method. However,
our re-analyses (Table 5) do provide evidence that this may be the case.
In all, in light of work that has assessed whether reported randomised trials conform to the recom-
mendations of the CONSORT guidance24, our findings should perhaps not be surprising. Nonetheless, it
may have been hoped that the simplicity of Simon’s design would lead to effective reporting. Our results
indicate that a CONSORT extension specific to the requirements of single-arm oncology trials may be
warranted.
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Figure 5: A comparison of the type-I error-rate and power of 45 trials that terminated in stage 2 and
specified α = 0.05 and 1 − β = 0.8, is given. In A and C, results are given for when the reported value
of a is retained with the sample size assumed in the analysis. In B and D, results are given when the
approach proposed by Englert and Kieser7 (EK) is implemented to account for deviation. Note that in
B, one trial does not attain the target type-I error-rate; this is a consequence of the original reported
design also not attaining the desired error-rate, and not an inadequacy of the methodology to account
for deviation.
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Supplementary materials to ‘Two-stage single-arm trials are
rarely reported adequately’
Supplementary methods
Two-stage group-sequential single-arm trial designs for a binary primary out-
come
In the main manuscript, we outlined the design of “Simon two-stage” trials. Here, we elaborate on the
statistical details of performing adjusted inference and handling design deviation in such studies.
First, let
b(s|m, p) =
(
m
s
)
ps(1− p)m−s,
B(s|m, p) =
s∑
i=0
b(i|m, p),
be the probability density and cumulative distribution function of a Bin(m, p) random variable. Next, let
sm =
∑m
i=1 xi be the number of successes seen for the primary outcome in the first m patients. Finally,
set a = (a1, a) and n = (n1, n). Then, define Uj(s|p,a,n) to be the probability that s successes are
observed by the end of stage j. We then have
U1(s|p,a,n) = b(s|n1, p),
U2(s|p,a,n) =
min(n1,s)∑
i=max{a1+1,s−(n−n1)}
b(i|n1, p)b(s− i|n− n1, p).
Any point-estimation procedure, Pˆ , must specify values for pˆ for all possible numbers of successes
that could be seen on trial termination at the end of each stage. We denote these values by pˆ = pˆ(s,m),
and then specifically we must have them for (s,m) = (0, n1), . . . , (a1, n1), (a1 + 1, n), . . . , (n, n).
As discussed, a ‘naive’ point estimation procedure, Pˆnaive, that does not account for the incorporated
interim analysis, sets pˆnaive(s,m) = s/m. In our work, we also consider six adjusted estimation procedures
that have been proposed in the literature. For this, some final notation is useful: for any point estimation
procedure Pˆ , we can compute its expected value and bias through
E(Pˆ |p,a,n) =
a1∑
s=0
pˆ(s, n1)U1{s|p,a,n}+
n∑
s=a1+1
pˆ(s, n)U2{s|p,a,n},
Bias(Pˆ |p,a,n) = E(Pˆ |p,a,n)− p.
The considered adjusted point estimates are then
• The bias-subtracted estimate25
pˆbias-sub(s,m) = pˆnaive(s,m)−Bias{Pˆnaive|pˆnaive(s,m),a,n}.
• The bias-adjusted estimate26, which is given by the numerical solution to
pˆbias-adj(s,m) = pˆnaive(s,m)−Bias{Pˆnaive|pˆbias-adj(s,m),a,n}.
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• The uniform minimum variance unbiased estimate19
pˆumvue(s,m) =

s
n1
: m = n1,∑min(s,n1)
i=max{a1+1,s−(n−n1)} (
n1−1
i−1 )(
n−n1
s−i )∑min(s,n1)
i=max{n1+1,s−(n−n1)} (
n1
i )(
n−n1
s−i )
: m = n.
• The uniform minimum variance conditionally unbiased estimate27
pˆumvcue(s,m) =

s
n1
: m = n1,∑min(s,n1)
i=max{a1+1,s−(n−n1)} (
n1
i )(
n−n1−1
s−i−1 )∑min(s,n1)
i=max{n1+1,s−(n−n1)} (
n1
i )(
n−n1
s−i )
: m = n.
• The conditional estimate28, which sets pˆcond(s,m) = s/m for m = n1. When m = n, pˆcond(s, n) is
the numerical maximiser of
− log
{
n1∑
i=a1+1
b(i|n1, p)
}
+ s log(p) + {(n− n1)− s} log(1− p).
• The median unbiased estimate23, which sets pˆmue(s,m) as the numerical solution to
q{s,m|pˆmue(s,m)} = 0.5,
where
q{s,m|p} =
1−B(s− 1|n1, p) : m = n1,∑n1
i=a1+1
b(i|n1, p){1−B(s− i− 1|n− n1, p)} : m = n,
.
We also consider two adjusted confidence interval (CI) procedures and several unadjusted CI pro-
cedures. As for the point estimation procedures above, any CI procedure, C, must specify c(s,m) =
(plow(s,m), pupp(s,m)) for all possible (s,m) combinations on trial termination. The first considered
adjusted CI procedure18 sets plow(s,m) and pupp(s,m) for a 100(1− α)% CI as the numerical solutions
to
q{s,m|plow(s,m)} = 1− α/2,
q{s,m|pupp(s,m)} = α/2.
The second procedure16, a mid-p approach, sets
∑
{(i,j):pˆumvue(i,j)>pˆumvue(s,m)}
Uj{i|plow(s,m),a,n}+ 0.5
∑
{(i,j):pˆumvue(i,j)=pˆumvue(s,m)}
Uj{i|plow(s,m),a,n} = 1− α/2,
and similarly for pupp(s,m).
We compare these to a number of standard unadjusted procedures, in particular Clopper-Pearson15,
which for s /∈ {0, n} sets
plow(s,m) =
[
1 +
m− s+ 1
sF−1{α/2, 2s, 2(m− s+ 1)}
]−1
,
pupp(s,m) =
[
1 +
m− s+ 1
(s+ 1)F−1{1− α/2, 2(s+ 1), 2(m− s)}
]−1
,
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where F−1(q, x, y) is the 100q% quantile of an F -distribution with x and y degrees of freedom. Supple-
menting this, c(0, n1) = (0, 1− (α/2)1/n1) and c(n, n) = ((α/2)1/n, 1).
For further information on the above, see Porcher and Desseaux16.
Finally, we describe how a determination can be made on H0 in the presence of design deviation.
Englert and Kieser7 provide comprehensive methodology for this by describing the decision rules for any
design in terms of a discrete conditional error function. Whilst they allow for the interim analysis being
conducted after any number of patients (i.e., a different value from that specified in the design), here we
describe handling of deviation only in the timing of the stage two analysis, as just one paper noted that
they conducted their interim analysis at an unplanned point. To determine whether to reject H0 at the
end of the second stage, if the analysis is conducted based on nan patients data (nan not necessarily equal
to n), a p-value based on the second stage data only is first computed
p2(snan − sn1 , nan − n1) = 1−B(snan − sn1 − 1|p0, nan − n1).
Then, H0 is rejected if p2(snan − sn1 , nan − n1) ≤ D(sn1 |a,n), for
D(s|a,n) =

0 : s ≤ a1,
1−B(a− s|p, n− n1) : a1 < s ≤ a,
1 : s > a.
Literature review
Inclusion criteria
As discussed in the main manuscript, PubMed was searched using the following term: (“2013/01/01”[Date
- Publication] : “2017/12/31”[Date - Publication]) AND Clinical Trial[Publication Type] AND (phase
II[Title/Abstract] OR phase 2[Title/Abstract]) AND (cancer[All Fields] OR oncology[All Fields]). Thus,
we reviewed clinical trial publications over a five year period, checking all such articles that included the
phrase ‘phase II’ or ‘phase 2’ in the title/abstract and the word ‘cancer’ or ‘oncology’ in any field.
We wished to include as many treatment arms as possible, whilst not biasing our findings. Our initial
inclusion criteria for arms reported in the returned records were therefore as follows:
• Accessible full-length articles. No short communications were allowed as the quality of reporting
would be expected to be lower in such articles. We required access to the complete text for inclusion.
• Primary publication on an arm’s complete results. No secondary or preliminary analyses were
allowed as the quality of reporting would be expected to be lower in such articles.
• Treatment arms designed and analysed using “Simon’s two-stage design”. Thus
– Treatment arms that were designed using Simon’s approach, but for which inference was
performed as if the primary outcome was a time-to-event variable (e.g., a dichotomised version
of PFS was used for design purposes, but inference was based on the exact PFS event-time data)
were to be excluded. These were to be excluded as we planned to re-analyse included arms
using appropriate adjusted methods for a binary primary outcome and compare our findings
to the reported results; such comparisons would not be logical across analysis frameworks.
– Treatment arms using Bayesian methods were to be excluded, as analysis and reporting of such
trials would be expected to differ (e.g., computation and reporting of adjusted point estimates
would be expected to be less frequent).
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– Treatment arms with p1 < p0 (e.g., where the primary outcome is toxicity) were to be excluded.
Though such trials could easily be analysed using adjusted procedures like those outlined above,
we anticipated some authors may not be aware of this.
– Treatment arms for which the design was intentionally modified were to be excluded. Such a
design would then correspond to an adaptive approach and not the considered group-sequential
design.
Five hundred and thirty four articles were randomly selected for evaluation for inclusion by MJG and
APM based on the above criteria. The authors agreed on inclusion for 520 articles (97.3%). The authors
disagreed on the remaining 12 articles for six reasons, which led to the following additional clarifications
on inclusion
• Treatment arms stated to have used “Simon’s two-stage design” but for which no additional infor-
mation was available to confirm this should be excluded (e.g., no reporting of stage-wise sample sizes
or other discussion of interim analysis). We felt inclusion of such articles would bias downwards the
identified quality of reporting and that presentation of what are likely conservative values in some
instances would be more appropriate.
• Treatment arms for which the results of sequential trials are reported simultaneously should be
excluded (e.g., simultaneous reporting of phase I and II results). We again felt inclusion of such
articles would potentially bias our results, as substantial focus may not be given to the Simon-
designed component. In some cases, it was also unclear as to whether data had been combined
across phases and if re-analysis using the considered adjusted inference procedures would then be
appropriate.
• Arms from articles reporting the results of multiple treatment arms should be included only if
each arm was designed and analysed independently (e.g., the overarching design could not be a
randomised selection approach, or similar). We anticipated these trials may focus more on arm
differences and not on evaluating point estimates or confidence intervals for each arm separately.
• Treatment arms for which it was stated formal interim monitoring of toxicity was performed should
be excluded. Such trials would be more similar to a Bryant and Day29 type approach than Simon’s
methodology.
• Treatment arms stated to have been designed using “Fleming’s” approach30 should be excluded,
as we felt such trials may not report interim sample sizes or stopping rules as frequently given the
way Fleming designs are identified.
• Treatment arms for which it was stated there was more than one primary outcome should be
excluded. For one article it was not clear how a second primary outcome may have influenced
design, analysis, and reporting. We therefore decided to exclude all subsequent articles with more
than one primary outcome.
A decision was then taken that given there was by enlarge agreement on inclusion, the remaining
articles were to be assessed for inclusion by MJG only, but that discussion with APM would be conducted
if required for any individual article.
Data extraction
For each of the 534 articles reviewed by both authors, a pilot duplicate data extraction was performed for
the treatment arms they deemed to be eligible for inclusion. In total, data was extracted by both authors
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for 58 eligible treatment arms; in each case data was extracted for 28 questions. These were Questions
1, 4, 5, 7-13, 15, 18-21, and 23-34 from Table 1 in the main manuscript, along with “What was the total
number of efficacy evaluable patients?”. Following the pilot evaluation, this last question was deemed to
be an unsuitable method of extracting data that would facilitate trial re-analyses, as some studies did not
utilise the number of evaluable patients in their analysis. This was therefore replaced by Question 22, “If
‘Yes’ to Q21, what was the sample size assumed in the analysis?”. Following the pilot data extraction,
the remaining questions listed in Table 1 (Questions 2, 3, 6, 14, 16, and 17) were also added to enhance
our evaluation. Data for these additional questions was subsequently extracted by MJG for those arms
included during the pilot.
We are thus able to evaluate the replicability of extraction across 58 treatment arms and 27 of the
final questions used for our results. As discussed in the main manuscript, across 14 questions requiring
non-binary value extraction (Questions 4, 5, 7-13, 20, 23, 26, 33, 34), the duplicate extractions agreed
96.2% of the time. Across a wider set of 26 questions (all except Question 1, which we omit as equality
for this is implied by performing a comparison), agreement occurred 94.3% of the time. With replicability
high, duplicate extraction was not performed for the remaining included arms.
Note that data was extracted from the included articles and their supplementary materials, but not
from any linked protocols. This is because we believed all questions amounted to critical information
that should be present in the primary publication reporting a trial’s results.
Trial re-analyses
For those trials that reported a point estimate or CI not stated to have been adjusted, the reported
results were re-analysed were possible to evaluate consistency with unadjusted and adjusted procedures.
We limited this re-analysis to those trials that terminated in stage two, for as can be seen above, point
estimation and CI procedures typically only modify standard inferential methods if a trial proceeds
to stage two. To this end, denote the number of realised patients assumed in the two analyses by
nan = (n1, nan), where nan is that extracted in Question 22.
First, the reported point estimate was checked for consistency with pˆnaive to the reported number of
decimal places. For example, suppose the data for Questions 22 and 23 indicate 21 patients were assumed
in the analysis with 7 successes, and Question 25 indicates that the reported point estimate was 0.33.
This would be consistent with pˆnaive to the reported number of decimal places, as pˆnaive = 7/21 = 0.33
to 2 decimal places. So long as a1 and n1 were also reported clearly (Questions 10 and 12), this point
estimate was also evaluated for whether it was consistent with each of the six adjusted point estimates
described earlier.
An equivalent approach was performed to evaluate whether any reported CI was consistent with
one of four unadjusted (Clopper-Pearson, Wald, Wilson, and Blyth-Still-Casella; the four unadjusted CI
methods stated to have been used by any included article across our review) and two adjusted CIs (those
given earlier).
For those included treatment arms that reported a 95% CI, we also compared the coverage provided by
their CI procedure to the adjusted method of Jennison and Turnbull18 when the true success probability
is pˆumvue. To this end, note that coverage can be computed for any p and C via
Cover(C|p,a,nan) =
a1∑
i=0
I{p ∈ c(s, n1)}U1(s|p,a,nan) +
n∑
i=a1
I{p ∈ c(s, nan)}U2(s|p,a,nan).
Finally, Figure 5 compares the unconditional operating characteristics for the sample sizes given in
nan, when either a is retained, or the method of Englert and Kieser
7 described earlier is implemented.
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For example, we compare the type-I error-rates via
P (Reject H0 when a is retained |p0,a,nan) =
nan∑
s=a+1
U2(p0,a,nan),
P (Reject H0 when EK is used |p0,a,nan) =
n1∑
s=0
b(s|p0, n1)[P{P2(p, nan − n1) ≤ D(s|a,n)}],
where P2(p0, nan−n1) is the random variable denoting the distribution of the second stage p-value under
the boundary of H0 for a second stage sample size of nan − n1. Power is compared similarly.
Supplementary results
Additional result interpretation approaches
Extending Figure 5, Supplementary figure 1 provides the probability of several quantities that trials
were routinely observed to use in the interpretation of their results. These are: P(Pˆnaive > p0|p0),
P(Pˆnaive > p0|p1), P(Pˆnaive ≥ p1|p0), and P(Pˆnaive ≥ p1|p1). Note that, e.g., the first quantity is computed
as
P(Pˆnaive > p0|p0) =
a1∑
s=0
I(pˆnaive(s, n1) > p0)U1(s|p0,a,nan)+
nan∑
s=a1+1
I(pˆnaive(s, nan) > p0)U2(s|p0,a,nan),
and similarly for the others.
Observe that the quantities conditioned on p0 do not generally take values close to the target type-I
error-rate 0.05. Similarly, the quantities conditioned on p1 are not generally close to the target power
0.8.
Included articles that reported the results of more than one eligible treatment arm
Supplementary Tables 1-4 and Supplementary Figures 2-5 display the corresponding results to those
given in the main manuscript for the 204 treatment arms that were included across the 75 articles that
reported the results of more than one eligible treatment arm.
The results are qualitatively similar to those presented in the main manuscript. In particular, for
only 26.0% of the 204 treatment arms were p0, p1, α, β, the optimality criteria, a1, a, n1, and n reported
clearly. Adjusted point estimates (4 arms, 2.0%) and adjusted confidence intervals (12 arms, 5.9%) were
again rarely reported, with little evidence to suggest that adjusted methods had been utilised with this
unstated (Supplementary table 4).
Note that a larger proportion of the 204 treatment arms described here (53.9%) were judged to have
ended in stage one than for the 425 treatment arms described in the main manuscript (25.9%). This is
a consequence of many multi-arm trials struggling to recruit in treatment arms for rare conditions.
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Supplementary figure 1: A comparison of the probabilities associated with several methods for interpreting
the results of a two-stage single-arm trial. Values are given for 45 trials that terminated in stage 2 and
specified α = 0.05 and 1− β = 0.8.
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Supplementary table 1: Descriptors on the 204 treatment arms that were included across the 75 articles
that reported the results of more than one eligible treatment arm. The denominators for computing
percentages (given to 1 decimal place) are 75 and 204 respectively in all instances.
Descriptor Value By article By arm
Number (%) Number (%)
Publication 2013 21 (28.0) 55 (27.0)
year 2014 13 (17.3) 36 (17.6)
2015 23 (30.7) 69 (33.8)
2016 12 (16.0) 32 (15.7)
2017 6 (8.0) 12 (5.9)
Journal J Clin Onol 8 (10.7) 29 (14.2)
Ann Oncol 6 (8.0) 21 (10.3)
Pediatr Blood Cancer 3 (4.0) 19 (9.3)
Eur J Cancer 5 (6.7) 13 (6.4)
Lancet Oncol 6 (8.0) 13 (6.4)
J Neurooncol 4 (5.3) 11 (5.4)
Other (27 journals) 43 (57.3) 98 (48.0)
Cancer Lung 9 (12.0) 31 (15.2)
Lymph 9 (12.0) 21 (10.3)
Brain/CNS 7 (9.3) 17 (8.3)
Breast 7 (9.3) 16 (7.8)
Blood 5 (6.7) 14 (6.9)
Other 38 (50.7) 105 (51.5)
Stage of 1 N/A 110 (53.9)
termination 2: Stated the criteria had been met for progression N/A 40 (19.6)
2: Did not state the criteria had been met for progression N/A 43 (21.1)
Unclear N/A 11 (5.4)
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Supplementary table 2: Reporting of the design of the 204 treatment arms that were included across
the 75 articles that reported the results of more than one eligible treatment arm. The denominator for
computing percentages (given to 1 decimal place) is 204 in all instances.
Criteria Number (%)
Used the phrase “Simon two-stage” (or similar) or cited Simon (1989)4 157 (77.0)
Clearly stated p0 192 (94.1)
Gave a justification for p0 43 (21.1)
Citation given 32 (15.7)
Justification given but no citation 11 (5.4)
Clearly stated p1 191 (93.6)
Clearly stated α 173 (84.8)
α = 0.05 57 (27.9)
α = 0.1 76 (37.3)
Clearly stated β 173 (84.8)
β = 0.1 95 (46.6)
β = 0.2 40 (19.6)
Clearly stated the optimality criteria 112 (54.9)
Null-optimal 69 (33.8)
Minimax 41 (20.1)
Admissable 0 (0)
Other 2 (1.0)
Clearly stated a1 165 (80.9)
Clearly stated a 130 (63.7)
Clearly stated n1 176 (86.3)
Clearly stated n 163 (79.9)
Indicated the recruitment target was greater than n 32 (15.7)
Clearly stated p0 and p1 185 (90.7)
Clearly stated p0, p1, α, and β 164 (80.4)
Clearly stated a1, a, n1, and n 130 (63.7)
Clearly stated p0, p1, α, β, and the optimality criteria 86 (42.2)
Clearly stated p0, p1, α, β, the optimality criteria, a1, a, n1, and n 53 (26.0)
Supplementary table 3: Reporting of inferential procedures performed in the 204 treatment arms that
were included across the 75 articles that reported the results of more than one eligible treatment arm, with
additional stratification by stage of termination. The denominators for computing percentages (given to
1 decimal place) in the three columns are 110, 83, and 204 respectively unless stated otherwise.
Criteria Stage 1 Stage 2 All
Number (%) Number (%) Number (%)
Reported a point estimate, p-value, or confidence 72 (65.5) 81 (97.6) 163 (79.9)
interval for the primary outcome
Reported a point estimate 72 (65.5) 81 (97.6) 163 (79.9)
Stated the point estimate had been adjusted for 0 (0) 4 (4.8) 4 (2.0)
the two-stage design
Reported a p-value 0 (0) 0 (0) 0 (0)
Stated the p-value had been adjusted for the 0 (0) 0 (0) 0 (0)
two-stage design
Reported a confidence interval 28 (25.5) 57 (68.7) 93 (45.6)
Stated the confidence interval had been 1 (0.9) 9 (10.8) 12 (5.9)
adjusted for the two-stage design
Analysis performed assuming a sample equal 14/57 (24.6) 13/73 (17.8) 27/130 (20.8)
to that given in the design
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Supplementary table 4: Re-analysis of arms from articles that reported the results of more than one
eligible treatment arm, which reported a point estimate or confidence interval not stated to have been
adjusted. Consistency is measured in all cases against the reported number of decimal places. The
denominators for computing percentages (given to 1 decimal place) are given in each row. Note that the
re-analysis is limited to those articles that were judged to have terminated in stage 2.
Criteria Number (%)
Reported a point estimate not stated as adjusted and clearly reported the 77/83 (92.8)
number of successes and sample size assumed in the analysis
Reported point estimate consistent with an unadjusted estimate 75/77 (97.4)
Reported point estimate consistent with at least one adjusted estimate 35/66 (53.0)
Reported a confidence interval not stated as adjusted and clearly reported its
level, the number of successes, and sample size assumed in the analysis 48/84 (57.1)
Reported confidence interval consistent with at least one unadjusted interval 37/48 (77.1)
Reported confidence interval consistent with at least one adjusted interval 2/44 (4.5)
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Supplementary figure 2: The combinations of p0 and p1 given for 185/204 arms (90.7%) in the 75 included
articles that reported the results of more than one eligible treatment arm. The size of the circles indicates
the number of arms that had a particular combination. Densigrams are given on the axes to display the
marginal distributions of p0 and p1. The dotted lines indicate the lower (0.15) and upper (0.25) quartiles
of the distribution of p1 − p0; the dashed line indicates the median (0.2) of this distribution.
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Supplementary figure 3: In A, a comparison of the naive unadjusted point estimate (pˆnaive) and the
uniform minimum variance unbiased estimate (UMVUE, pˆumvue) is given for 68 arms that terminated
in stage 2 where the UMVUE could be computed. In B, the difference between pˆnaive and pˆumvue is
presented as a percentage of p1 − p0, along with a boxplot to indicate the distribution of this data.
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Supplementary figure 4: In A, the length of the reported unadjusted CI is compared to the length of
the corresponding adjusted CI proposed by Jennison and Turnbull18 for the 43 arms for which this
adjusted CI could be computed. In B, the respective coverage of these unadjusted and adjusted CIs when
p = pˆumvue is given for the 36 of these arms in which the target coverage was 0.95. In both cases, points
are coloured by the unadjusted CI that the re-analysis indicated the reported CI matched with. For those
CIs that matched none of the unadjusted CIs, Clopper-Pearson15 was used to compute the coverage.
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Supplementary figure 5: A comparison of the sample size required by the design and that assumed in the
analysis for 193 articles. Colour indicates the judged stage of trial termination.
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